Evidence map›Paper›PMID 36771288›Full record

ReviewNutrients2023

Dietary Exposures and Interventions in Inflammatory Bowel Disease: Current Evidence and Emerging Concepts.

John Gubatan, Chiraag V Kulkarni, Sarah Melissa Talamantes, Michelle Temby, Touran Fardeen, Sidhartha R Sinha

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06683105 (A Pilot Randomized Trial Investigating the MyIBDDiet App to Improve Self-management of an Anti-inflammatory Diet for Individuals With Inflammatory Bowel Disease), which is not on this map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06683105 narecruitingnot on this mapstarted 2026, after this paper: background citation

A Pilot Randomized Trial Investigating the MyIBDDiet App to Improve Self-management of an Anti-inflammatory Diet for Individuals With Inflammatory Bowel Disease

TypeinterventionalSponsorUniversity of AlbertaRan2026 to 2029Enrolled40ConditionsInflammatory Bowel Disease (IBD)ArmsMyIBDDiet app
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Incorporating Real-World Variability in Clinical IBD Research.Journal of evaluation in clinical practice · 2025
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Observational
  16. Review
  17. Key Interleukins in Inflammatory Bowel Disease-A Review of Recent Studies.International journal of molecular sciences · 2024
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

John GubatanDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0001-6037-2883
Chiraag V KulkarniDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-8354-3566
Sarah Melissa TalamantesDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Michelle TembyDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Touran FardeenDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0001-6050-740X
Sidhartha R SinhaDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0001-5104-6410
Stanford University · USChan Zuckerberg Initiative (United States) · US

Funding

NIDDK NIH HHS L30 DK126220
6 · The paper itself

Abstract

Diet is intimately linked to the gastrointestinal (GI) tract and has potent effects on intestinal immune homeostasis. Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the GI tract. The therapeutic implications of diet in patients with IBD have received significant attention in recent years. In this review, we provide a contemporary and comprehensive overview of dietary exposures and interventions in IBD. Epidemiological studies suggest that ultra-processed foods, food additives, and emulsifiers are associated with a higher incidence of IBD. Exclusion and elimination diets are associated with improved symptoms in patients with IBD, but no effects on objective markers of inflammation. Specific dietary interventions (e.g., Mediterranean, specific carbohydrate, high fiber, ketogenic, anti-inflammatory diets) have been shown to reduce symptoms, improve inflammatory biomarkers, and quality of life metrics to varying degrees, but these studies are limited by study design, underpowering, heterogeneity, and confounding. To date, there is no robust evidence that any dietary intervention alone may replace standard therapies in patients with IBD. However, diet may play an adjunct role to induce or maintain clinical remission with standard IBD therapies. The results of novel dietary trials in IBD such as personalized fiber, intermittent fasting, and time-restricted diets are eagerly awaited.

Indexed as

Inflammatory Bowel DiseasesQuality of LifeDietDietary ExposureHumansInflammationclinical trialsCrohn’s diseasedietepidemiologyfoodinflammatory bowel diseaseulcerative colitis

Identifiers

PMID36771288
PMCPMC9921630
OpenAlexW4317738344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.